In multiple sclerosis (MS), PML has been associated with the use of Tysabri. Three people developed PML while using Tysabri (2 died and one became severely disabled), which caused Tysabri to be temporarily withdrawn from the market. It was reintroduced to the market when several procedures to monitor for new cases of PML were introduced. It is thought that PML was linked to the combination of Tysabri with other immunomodulating or immunosuppressive drugs.

